Core Viewpoint - BrainsWay Ltd. is a leader in noninvasive brain stimulation technologies, focusing on advancing neuroscience through its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform, which has received FDA clearance for multiple mental health disorders [2]. Group 1: Company Overview - BrainsWay is recognized for its advanced neurostimulation treatments aimed at mental health disorders, with a commitment to improving health and transforming lives [2]. - The company has achieved FDA clearance for three indications: major depressive disorder, obsessive-compulsive disorder, and smoking addiction, supported by pivotal clinical studies [2]. - Founded in 2003, BrainsWay operates in the United States and Israel, with ongoing clinical trials for Deep TMS in various psychiatric, neurological, and addiction disorders [2]. Group 2: Upcoming Events - Management from BrainsWay will participate in one-on-one meetings at the Citi 2026 Unplugged MedTech and Life Sciences Access Day on February 26, 2026, in New York [1].

Core Insights - BrainsWay Ltd. comments on Evernorth Behavioral Health's decision to eliminate prior authorization for transcranial magnetic stimulation (TMS), effective March 6, 2026, which will enhance patient access to TMS therapy [1][2] Group 1: Company Overview - BrainsWay is a global leader in advanced noninvasive brain stimulation technologies, particularly known for its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform [5] - The company has obtained three FDA-cleared indications for Deep TMS, which include major depressive disorder, obsessive-compulsive disorder, and smoking addiction, supported by pivotal clinical studies [5] Group 2: Industry Impact - Evernorth's policy change is expected to reduce administrative hurdles, allowing providers to focus on patient care and improving treatment access for individuals with major depressive disorder and obsessive-compulsive disorder [2][3] - The change is anticipated to provide timely access to evidence-based treatment for eligible patients, many of whom have not found relief through traditional therapies [3] Group 3: Future Directions - BrainsWay continues to lead in neurostimulation therapies through ongoing clinical research and collaborations aimed at expanding access to these treatments [4]

Core Insights - Highmark Blue Cross Blue Shield has released a draft medical policy expanding coverage for adolescent and adult patients with major depressive disorder (MDD) to include BrainsWay's accelerated Deep TMS™ protocol [1][2] - The new policy is expected to take effect in February 2026, following an open comment period, and will cover BrainsWay's accelerated SWIFT™ protocol, which involves a total of 38 treatment sessions [2] - BrainsWay's accelerated depression protocol for Deep TMS received FDA clearance in September 2025, demonstrating an 87.8% response rate and a 78.0% remission rate in clinical trials [4] Company Overview - BrainsWay is a leader in noninvasive neurostimulation treatments for mental health disorders, with a proprietary Deep TMS™ platform technology [5] - The company has obtained three FDA-cleared indications for its treatments, including major depressive disorder, obsessive-compulsive disorder, and smoking addiction [5] - BrainsWay is committed to advancing neuroscience and increasing global awareness and access to Deep TMS [5]